October 10, 2018
 It is anticipated that RIPPLE (Roster Interface Program and Participants List Environment) version 3.0 will be rolled out on October 19, 2018. Read More |
 Canadian Cancer Trials group is providing an update about the previously planned BI.3 trial "A Phase II/III Trial Comparing Cisplatin Plus Acelarin to Cisplatin Plus Gemcitabine in First-Line Treatment of Locally Advanced or Metastatic Biliary Tract Cancer". The BI.3 trial will not be proceeding to move forward through the planned academic consortium as lead by CCTG, the partnering company has made a strategic decision to undertake the study as an industry-sponsored trial. Read More |
 The CCTG trial team, is happy to announce that the IND.211 trial has now officially closed. No further ethics approvals or follow-up data are required. The notification of permanent trial closure is posted on the CCTG website in the "Toolbox" and on the IND.211 trial page:https://www.ctg.queensu.ca/docs/trials/permanent_closure/I211-CTG-led-Final%20Letter_to_Cdn_sites.pdf
Read More |
 Why are cancer clinical trials important? Find out in this video interview with Dr. Rebecca Auer. Read More |
International research collaboration explores blood-based biomarker testingPublished: October 10, 2018Category: News  A new trial, Nivolumab, Ipilimumab in Patients With Hyper Mutated Cancers Detected in Blood (NIMBLe) will soon open at centers in the US and Canada. Trial researchers will initially explore the use of non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy. Read More |
September 26, 2018
 IND.210 A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Al one in Patients with Metastatic Colorectal Cancer Read More |
 On Wednesday September 19th 2018, CCTG's Director, Dr. Janet Dancey aired on the Blind Date with Knowledge radio show. During her interview Dr. Dancey talks about Evolving Clinical Trials through Collaboration. She discussed how the collaborative study of medical interventions in the treatment of cancer has expanded to also investigate how lifestyle, radiation, surgical, and smoke cessation interventions can affect the entire spectrum of cancer treatment. Read More |
Publication - Design and conduct of early clinical studies of immunotherapy agent combinationsPublished: September 26, 2018Category: Publications  Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G. Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (ONLINE) Ann Oncol mdy398, 2018. Read More |